• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapy and medications are not effective. A customized treatment could be the answer.

Cue is an intervention platform that transforms passively acquired sensor data from smartphones into customized micro-interventions that improve mental health. We looked at the best-fitting personal ML models for each individual using Shapley values, in order to understand their features and predictors. The results revealed distinct characteristics that changed mood in a predictable manner over time.

Predictors of Mood

depression treatments is a leading cause of mental illness in the world.1 Yet, only half of those suffering from the condition receive treatment. To improve the outcomes, healthcare professionals must be able to identify and treat patients with the highest chance of responding to certain treatments.

Personalized depression treatment is one method to achieve this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit most from specific treatments. They use sensors for mobile phones, a voice assistant with artificial intelligence as well as other digital tools. With two grants awarded totaling more than $10 million, they will make use of these tools to identify the biological and behavioral factors that determine response to antidepressant medications and psychotherapy.

The majority of research to so far has focused on sociodemographic and clinical characteristics. These include demographics such as gender, age, and education, and clinical characteristics like severity of symptom and comorbidities as well as biological markers.

While many of these factors can be predicted from the information in medical records, few studies have utilized longitudinal data to explore predictors of mood in individuals. A few studies also take into account the fact that mood can be very different between individuals. Therefore, it is crucial to create methods that allow the recognition of the individual differences in mood predictors and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behaviour and emotions that are unique to each individual.

The team also created a machine learning algorithm to model dynamic predictors for each person's depression mood. The algorithm blends these individual variations into a distinct "digital phenotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, a psychometrically validated symptom severity scale. However the correlation was tinny (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely across individuals.

Predictors of symptoms

Depression is one of the leading causes of disability1, but it is often underdiagnosed and undertreated2. Depression disorders are rarely treated because of the stigma associated with them and the lack of effective treatments.

To help with personalized treatment, it is essential to identify the factors that predict symptoms. However, current prediction methods depend on the clinical interview which is not reliable and only detects a tiny number of symptoms that are associated with depression.2

Using machine learning to blend continuous digital behavioral phenotypes captured through smartphone sensors and an online tracker of mental health (the Computerized Adaptive Testing Depression Inventory, CAT-DI) together with other predictors of severity of symptoms can increase the accuracy of diagnostics and treatment efficacy for depression. Digital phenotypes are able to are able to capture a variety of unique actions and behaviors that are difficult to record through interviews, and also allow for high-resolution, continuous measurements.

The study included University of California Los Angeles students who had mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online assistance or in-person clinics depending on their depression severity. Those with a score on the CAT-DI scale of 35 65 students were assigned online support by the help of a coach. Those with a score 75 were sent to clinics in-person for psychotherapy.

Participants were asked a series questions at the beginning of the study concerning their demographics and psychosocial characteristics. These included sex, age, education, work, and financial status; if they were partnered, divorced, or single; current suicidal ideation, intent, or attempts; and the frequency with which they drank alcohol. The CAT-DI was used to assess the severity of depression symptoms on a scale ranging from zero to 100. The CAT-DI test was performed every two weeks for those who received online support, and weekly for those who received in-person support.

Predictors of electromagnetic treatment for depression Response

A customized treatment for depression is currently a research priority and many studies aim to identify predictors that help clinicians determine the most effective medications for each person. Pharmacogenetics, in particular, is a method of identifying genetic variations that affect how the human body metabolizes drugs. This allows doctors to select drugs that are likely to work best for each patient, minimizing the time and effort involved in trial-and-error procedures and eliminating any side effects that could otherwise slow advancement.

Another promising method is to construct models of prediction using a variety of data sources, combining data from clinical studies and neural imaging data. These models can then be used to determine the most appropriate combination of variables that is predictive of a particular outcome, like whether or not a drug is likely to improve symptoms and mood. These models can also be used to predict the patient's response to treatment for depression and anxiety - https://clashofcryptos.trade/wiki/Why_You_Should_Concentrate_On_Improving_Finding_The_Right_Depression_Treatment, that is already in place which allows doctors to maximize the effectiveness of treatment currently being administered.

A new generation employs machine learning techniques such as algorithms for classification and supervised learning such as regularized logistic regression, and tree-based methods to integrate the effects from multiple variables and increase the accuracy of predictions. These models have been demonstrated to be useful in predicting the outcome of treatment for example, the response to antidepressants. These models are getting more popular in psychiatry, and it is expected that they will become the norm for the future of clinical practice.

In addition to the ML-based prediction models The study of the underlying mechanisms of hormonal depression treatment continues. Recent research suggests that treating depression is connected to dysfunctions in specific neural networks. This suggests that an individualized treatment for depression will depend on targeted therapies that restore normal functioning to these circuits.

One method of doing this is by using internet-based programs which can offer an individualized and personalized experience for patients. A study showed that a web-based program improved symptoms and provided a better quality of life for MDD patients. A controlled, randomized study of a personalized treatment for depression revealed that a significant number of participants experienced sustained improvement and had fewer adverse negative effects.

Predictors of Side Effects

In the treatment of depression, the biggest challenge is predicting and identifying which antidepressant medication will have very little or no side effects. Many patients have a trial-and error method, involving various medications being prescribed before settling on one that is safe and effective. Pharmacogenetics is an exciting new method for an effective and precise approach to choosing antidepressant medications.

A variety of predictors are available to determine which antidepressant to prescribe, such as gene variants, phenotypes of patients (e.g. gender, sex or ethnicity) and co-morbidities. To identify the most reliable and accurate predictors of a specific treatment, random controlled trials with larger numbers of participants will be required. This is because the detection of interactions or moderators could be more difficult in trials that take into account a single episode of treatment per person, rather than multiple episodes of treatment over time.

Additionally to that, predicting a patient's reaction will likely require information on comorbidities, symptom profiles and the patient's own perception of the effectiveness and tolerability. At present, only a handful of easily measurable sociodemographic variables as well as clinical variables are consistently associated with response to MDD. These include gender, age, race/ethnicity as well as BMI, SES and the presence of alexithymia.

The application of pharmacogenetics to depression treatment is still in its early stages and there are many hurdles to overcome. It is crucial to have a clear understanding and definition of the genetic mechanisms that underlie depression, as well as a clear definition of a reliable indicator of the response to treatment. Additionally, ethical issues such as privacy and the appropriate use of personal genetic information, must be considered carefully. In the long run pharmacogenetics can be a way to lessen the stigma associated with mental health care and improve the outcomes of those suffering with depression. However, as with any other psychiatric treatment, careful consideration and implementation is essential. For now, the best option is to provide patients with various effective depression medication options and encourage them to speak freely with their doctors about their experiences and concerns.